Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage ...

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the ...

Hims & Hers (HIMS) stock jumped 7% after partnering with Eli Lilly for GLP-1 drugs. J.P. Morgan initiated coverage with a $35 target and Overweight rating.

In recent days, Hims & Hers Health expanded its platform so clinicians can prescribe Eli Lilly GLP‑1 weight loss treatments, such as Zepbound vials, KwikPen, and Foundayo, with fulfillment routed ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors ...

Telehealth investors weigh Amazon’s new anti-obesity drug push against this platform’s recent rapid growth, today, April 21, ...

April 22 (Reuters) - Telehealth company Hims & Hers said on Wednesday it will now offer treatment options for perimenopause ...

S&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across ...

By Sneha S K April 16 (Reuters) - Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U.S. drug ...

Hims & Hers (HIMS) stock is in focus as the company expands offerings to menopause care, with sales of estrogen patch kits starting at $134 per month. Read more here.